All Title Author
Keywords Abstract

PLOS ONE  2011 

Association of CD40 Gene Polymorphisms with Sporadic Breast Cancer in Chinese Han Women of Northeast China

DOI: 10.1371/journal.pone.0023762

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background Breast cancer is a polygenetic disorder with a complex inheritance pattern. Single nucleotide polymorphisms (SNPs), the most common genetic variations, influence not only phenotypic traits, but also interindividual predisposition to disease, treatment outcomes with drugs and disease prognosis. The co-stimulatory molecule CD40 plays a prominent role in immune regulation and homeostasis. Accumulating evidence suggests that CD40 contributes to the pathogenesis of cancer. Here, we set out to test the association between polymorphisms in the CD40 gene and breast carcinogenesis and tumor pathology. Methodology and Principal Findings Four SNPs (rs1800686, rs1883832, rs4810485 and rs3765459) were genotyped by the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method in a case-control study including 591 breast cancer patients and 600 age-matched healthy controls. Differences in the genotypic distribution between breast cancer patients and healthy controls were analyzed by the Chi-square test for trends. Our preliminary data showed a statistically significant association between the four CD40 gene SNPs and sporadic breast cancer risk (additive P = 0.0223, 0.0012, 0.0013 and 0.0279, respectively). A strong association was also found using the dominant, recessive and homozygote comparison genetic models. In the clinical features analysis, significant associations were observed between CD40 SNPs and lymph node metastasis, human epidermal growth factor receptor 2 (C-erbB2), estrogen receptor (ER), progesterone receptor (PR) and tumor protein 53 (P53) statuses. In addition, our haplotype analysis indicated that the haplotype Crs1883832Grs4810485, which was located within the only linkage disequilibrium (LD) block identified, was a protective haplotype for breast cancer, whereas Trs1883832Trs4810485 increased the risk in the studied population, even after correcting the P value for multiple testing (P = 0.0337 and 0.0430, respectively). Conclusions and Significance Our findings primarily show that CD40 gene polymorphisms contribute to sporadic breast cancer risk and have a significant association with clinicopathological features among Chinese Han women from the Heilongjiang Province.

References

[1]  Pal R, Gochhait S, Chattopadhyay S, Gupta P, Prakash N, et al. (2011) Functional implication of TRAIL ?716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor. Breast Cancer Res Treat 126: 333–343.
[2]  Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, et al. (2009) Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229: 152–172.
[3]  Purkerson JM, Smith RS, Pollock SJ, Phipps RP (2005) The TRAF6, but not the TRAF2/3, binding domain of CD40 is required for cytokine production in human lung fibroblasts. Eur J Immunol 35: 2920–2928.
[4]  Tan J, Town T, Mori T, Obregon D, Wu Y, et al. (2002) CD40 is expressed and functional on neuronal cells. EMBO J 21: 643–652.
[5]  Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW (1998) CD40 and epithelial cells: across the great divide. Immunol Today 19: 502–506.
[6]  Hollenbaugh D, Mischel-Petty N, Edwards CP, Simon JC, Denfeld RW, et al. (1995) Expression of functional CD40 by vascular endothelial cells. J Exp Med 182: 33–40.
[7]  Murugaiyan G, Martin S, Saha B (2007) CD40-induced countercurrent conduits for tumor escape or elimination? Trends Immunol 28: 467–473.
[8]  Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, et al. (2007) Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25: 876–883.
[9]  Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, et al. (2009) Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res 15: 1317–1325.
[10]  Baxendale AJ, Dawson CW, Stewart SE, Mudaliar V, Reynolds G, et al. (2005) Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene 24: 7913–7923.
[11]  Deregibus MC, Buttiglieri S, Russo S, Bussolati B, Camussi G (2003) CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J Biol Chem 278: 18008–18014.
[12]  Flaxenburg JA, Melter M, Lapchak PH, Briscoe DM, Pal S (2004) The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol 172: 7503–7509.
[13]  Melter M, Reinders ME, Sho M, Pal S, Geehan C, et al. (2000) Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96: 3801–3808.
[14]  Dolen Y, Yilmaz G, Esendagli G, Guler NE, Guc D (2010) CD40 -1C>T single nucleotide polymorphism and CD40 expression on breast tumors. Cytokine 50: 243–244.
[15]  Skibola CF, Nieters A, Bracci PM, Curry JD, Agana L, et al. (2008) A functional TNFRSF5 gene variant is associated with risk of lymphoma. Blood 111: 4348–4354.
[16]  Jacobson EM, Concepcion E, Oashi T, Tomer Y (2005) A Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology 146: 2684–2691.
[17]  Jacobson EM, Huber AK, Akeno N, Sivak M, Li CW, et al. (2007) A CD40 Kozak sequence polymorphism and susceptibility to antibody-mediated autoimmune conditions: the role of CD40 tissue-specific expression. Genes Immun 8: 205–214.
[18]  Loskog AS, Eliopoulos AG (2009) The Janus faces of CD40 in cancer. Semin Immunol 21: 301–307.
[19]  Kozak M (1987) An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 15: 8125–8148.
[20]  Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109: 1721–1728.
[21]  Lee JS, Lo PK, Fackler MJ, Argani P, Zhang Z, et al. (2007) A comparative study of Korean with Caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in Korean women. Cancer Biol Ther 6: 1114–1120.
[22]  Stendahl M, Rydén L, Nordenskj?ld B, J?nsson PE, Landberg G, et al. (2006) High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12: 4614–4618.
[23]  Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, et al. (2001) Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg 233: 630–638.
[24]  Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, et al. (2000) c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 73: 17–20.

Full-Text

comments powered by Disqus